The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia

Overview

Journal Front Pharmacol

Date 2019 Jun 14

PMID 31191302

Citations 17

Authors

Chieh-Hsin Lin

Hsien-Yuan Lane

Affiliations

Soon will be listed here.

Abstract

While the world's population is aging, the prevalence of dementia and the associated behavioral and psychological symptoms of dementia (BPSD) rises rapidly. BPSD are associated with worsening of cognitive function and poorer prognosis. No pharmacological treatment has been approved to be beneficial for BPSD to date. Dysfunction of the N-methyl-D-aspartate receptor (NMDAR)-related neurotransmission leads to cognitive impairment and behavioral changes, both of which are core symptoms of BPSD. Memantine, an NMDAR partial antagonist, is used to treat moderate to severe Alzheimer's disease (AD). On the other hand, a D-amino acid oxidase inhibitor improved early-phase AD. Whether to enhance or to attenuate the NMDAR may depend on the phases of dementia. It will be valuable to develop biomarkers indicating the activity of NMDAR, particularly in BPSD. In addition, recent reports suggest that gender difference exists in the treatment of dementia. Selecting subpopulations of patients with BPSD who are prone to improvement with treatment would be important. We reviewed literatures regarding the treatment of BPSD, focusing on the NMDAR-related modulation and precision medicine. Future studies examining the NMDAR modulators with the aid of potential biomarkers to tailor the treatment for individualized patients with BPSD are warranted.

Citing Articles

Caveolae with serotonin and NMDA receptors as promising targets for the treatment of Alzheimer's disease.

Nakashima M, Suga N, Fukumoto A, Yoshikawa S, Matsuda S Int J Physiol Pathophysiol Pharmacol. 2024; 16(5):96-110.

PMID: 39583750 PMC: 11579522. DOI: 10.62347/MTWV3745.

Targeting ion channels with ultra-large library screening for hit discovery.

Melancon K, Pliushcheuskaya P, Meiler J, Kunze G Front Mol Neurosci. 2024; 16:1336004.

PMID: 38249296 PMC: 10796734. DOI: 10.3389/fnmol.2023.1336004.

3,4-Dihydro-2(1)-Pyridones as Building Blocks of Synthetic Relevance.

Chalan-Gualan S, Castro V, Oropeza R, Suarez M, Albericio F, Rodriguez H Molecules. 2022; 27(16).

PMID: 36014305 PMC: 9416769. DOI: 10.3390/molecules27165070.

Diagnosing Alzheimer's Disease Specifically and Sensitively With pLG72 and Cystine/Glutamate Antiporter SLC7A11 AS Blood Biomarkers.

Lane H, Lin C Int J Neuropsychopharmacol. 2022; 26(1):1-8.

PMID: 35986919 PMC: 9850657. DOI: 10.1093/ijnp/pyac053.

The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer's Disease.

Wiatrak B, Balon K, Jawien P, Bednarz D, Jeskowiak I, Szelag A Int J Mol Sci. 2022; 23(9).

PMID: 35563253 PMC: 9104401. DOI: 10.3390/ijms23094862.

References

Tsai G, Falk W, Gunther J, Coyle J . Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999; 156(3):467-9. DOI: 10.1176/ajp.156.3.467. View

Shah A, Allen H . Is improvement possible in the measurement of behaviour disturbance in dementia?. Int J Geriatr Psychiatry. 1999; 14(7):512-9. View

Guerrero A, Dorado-Martinez C, Rodriguez A, Borgonio-Perez G, Rivas-Arancibia S . Effects of vitamin E on ozone-induced memory deficits and lipid peroxidation in rats. Neuroreport. 1999; 10(8):1689-92. DOI: 10.1097/00001756-199906030-00012. View

Wolosker H, Blackshaw S, Snyder S . Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A. 1999; 96(23):13409-14. PMC: 23961. DOI: 10.1073/pnas.96.23.13409. View

Fratiglioni L, De Ronchi D, Aguero-Torres H . Worldwide prevalence and incidence of dementia. Drugs Aging. 1999; 15(5):365-75. DOI: 10.2165/00002512-199915050-00004. View

Gusev E, Skvortsova V, Dambinova S, Raevskiy K, Alekseev A, Bashkatova V . Neuroprotective effects of glycine for therapy of acute ischaemic stroke. Cerebrovasc Dis. 2000; 10(1):49-60. DOI: 10.1159/000016025. View

Paulsen J, Salmon D, Thal L, Romero R, Galasko D, Hofstetter C . Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000; 54(10):1965-71. DOI: 10.1212/wnl.54.10.1965. View

Bickford P, Gould T, Briederick L, Chadman K, Pollock A, Young D . Antioxidant-rich diets improve cerebellar physiology and motor learning in aged rats. Brain Res. 2000; 866(1-2):211-7. DOI: 10.1016/s0006-8993(00)02280-0. View

Ilani T, Ben-Shachar D, Strous R, Mazor M, Sheinkman A, Kotler M . A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci U S A. 2001; 98(2):625-8. PMC: 14638. DOI: 10.1073/pnas.98.2.625. View

10.

Chen B, Dowlatshahi D, MacQueen G, Wang J, Young L . Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001; 50(4):260-5. DOI: 10.1016/s0006-3223(01)01083-6. View

11.

Stewart R, Chen B, Dowlatshahi D, MacQueen G, Young L . Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain Res Bull. 2001; 55(5):625-9. DOI: 10.1016/s0361-9230(01)00524-x. View

12.

Oranje B, Gispen-de Wied C, Verbaten M, Kahn R . Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol. Biol Psychiatry. 2002; 52(9):887-95. DOI: 10.1016/s0006-3223(02)01377-x. View

13.

Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R . A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64(2):134-43. DOI: 10.4088/jcp.v64n0205. View

14.

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H . Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348(14):1333-41. DOI: 10.1056/NEJMoa013128. View

15.

Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N . Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry. 2003; 60(6):572-6. DOI: 10.1001/archpsyc.60.6.572. View

16.

Ikonomidou C, Turski L . Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol. 2003; 1(6):383-6. DOI: 10.1016/s1474-4422(02)00164-3. View

17.

Harman D . Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956; 11(3):298-300. DOI: 10.1093/geronj/11.3.298. View

18.

Nagata Y . Involvement of D-amino acid oxidase in elimination of D-serine in mouse brain. Experientia. 1992; 48(8):753-5. DOI: 10.1007/BF02124295. View

19.

Fukui K, Miyake Y . Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. J Biol Chem. 1992; 267(26):18631-8. View

20.

Cossins E, Chan P, Combepine G . One-carbon metabolism in Neurospora crassa wild-type and in mutants partially deficient in serine hydroxymethyltransferase. Biochem J. 1976; 160(2):305-14. PMC: 1164237. DOI: 10.1042/bj1600305. View